Detect SARS-CoV-2 on the Fluxergy Platform

Image source: Fluxergy

1-Hour-RT-PCR

Detect SARS-CoV-2 on the Fluxergy Platform

Now Available: The Fluxergy Analyzer System is a testing platform designed for sample-to-answer point-of-care testing, enabling clinicians to cost-effectively conduct molecular in vitro diagnostic tests.

The analyzer system is designed to deliver test results within one hour. This device is solely intended to be used by healthcare professionals.

Photo

Image source: Fluxergy

The Fluxergy Diagnostic Testing System consists of:

  • Fluxergy Card - a single-use “lab-on-chip” consumable technology
  • Fluxergy Analyzer - a highly integrated detection system
  • Fluxergy Works software - an analysis and cybersecure communication platform for test data

Fluxergy’s simple workflow on a compact analyzer makes it ideal for use in laboratory or field settings. Potential environments for rapid testing applications include emergency rooms, outpatient procedures, urgent care, workplace screening, mobile testing, and community level testing settings. 

The Fluxergy Test Kit Covid-19, which utilizes state-of-the-art Sample-to-Answer-RT-PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in one hour.

Highly automated, with no extraction required

Historically, one of the biggest challenges in point-of-care PCR testing is the ability to automate the more labor-intensive extraction processes. The microfluidic technology embedded within the Fluxergy Card enables a highly efficient simplified workflow: No extraction and minimal hands-on time. Our goal is to make testing more accessible. We believe the technology embedded within the Fluxergy Analyzer System, with cost-effective and scalable test cards, could enable the widespread adoption of point-of-care testing.

  • Simple Workflow designed for rapid testing
  • Real-Time RT-PCR with no extraction required
  • Minimal hands-on time per sample
  • Assay Target: SARS-CoV-2 N-gene and orf1ab gene
  • Limit of Detection (LOD): 0.89 TCID50/mL of sample
  • Sample: NP swab in VTM.

The simple workflow of the Fluxergy Analyzer System:

Detect SARS-CoV-2 on the Fluxergy Platform

Image source: Fluxergy

About the Test

Identification of the SARS-CoV-2 virus occurs using target-specific primers and fluorescent-labeled probes that hybridize to a conserved region of the non-structural polyprotein (orf1ab) and the N gene of the SARS-CoV-2 virus. Each Fluxergy PCR Card consists of multiple polymerase chain reaction (PCR) chambers, each conducting its own PCR amplification, enabling more available data in every test.

The UC San Diego physician-scientist research team that evaluated the Fluxergy Test Kit has been led by Dr. Davey Smith, Professor of Medicine and Head of the UCSD Division of Infectious Diseases and Global Public Health. Dr. Smith is a member of the Fluxergy Medical Advisory Board.


About Fluxergy

Fluxergy was founded with the goal of building a platform that enables clinicians to cost-effectively conduct a wide range of sophisticated tests at the point of care. Fluxergy’s new manufacturing center is designed to produce up to one million PCR Covid-19 test kits per month. Fluxergy launched in 2013 with funding support from principal investor and Kingston Technology co-founder John Tu.

Learn more about our competitive pricing and request test kits at fluxergy.com


Source: Fluxergy

12.04.2021

Read all latest stories

Related articles

Photo

Precise, affordable, and portable

A health testing platform that consolidates multimodal and multiplex testing to one device

Fluxergy envisions that a fully articulated democratized testing health system has the potential to reduce the likelihood and the ultimate severity of pandemics like Covid-19. Our mission is to…

Photo

Portable testing solution

A corona lab that fits in a suitcase

The PCR test is the most accurate tool to identify SARS-CoV-2. However, valid results are often available only after days. Moreover, the laboratory must be well equipped, have trained personnel and…

Photo

Collaboration with Mammoth Biosciences

Merck to scale up new SARS-CoV-2 Test

Merck announced a collaboration with Mammoth Biosciences Inc. for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test.

Related products

Subscribe to Newsletter